Actively Recruiting
Dapagliflozin in Allo-HCT for aGVHD
Led by The First Affiliated Hospital of Soochow University · Updated on 2025-06-05
72
Participants Needed
1
Research Sites
87 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if Dapagliflozin could prevent acute graft-versus-host disease (aGVHD) in patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) with haploidentical or unrelated donor and to assess its safety. The main questions it aims to answer are: Dose Dapagliflozin lower the cumulative incidence of aGVHD? What medical problems do participants undergoing allo-HCT from haploidentical or unrelated donor have when taking Dapagliflozin? Researchers will document the occurrence of graft-versus-host disease, hematopoietic reconstitution, survival rates and adverse effects. Participants will take Dapagliflozin every day in -1 to 14 days.
CONDITIONS
Official Title
Dapagliflozin in Allo-HCT for aGVHD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 65 years old
- Patients with hematologic malignancies indicated for allo-HCT and having a suitable haploidentical or unrelated donor
- Willing to undergo myeloablative conditioning and graft-versus-host disease prophylaxis based on cyclosporin A and methotrexate
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-3
- Prior use of Dapagliflozin or other hypoglycemic medications allowed if switching to Dapagliflozin is approved by the treating physician
- Ability to provide informed consent and comply with study and follow-up procedures
You will not qualify if you...
- Having other malignancies
- Previous history of autologous hematopoietic cell transplantation, allo-HCT, or chimeric antigen receptor T-cell therapy
- Allergy to Dapagliflozin
- Type 1 diabetes or history of ketoacidosis
- History of recurrent urinary tract infections
- Severe organ dysfunction
- Active infection with hepatitis B virus, hepatitis C virus, or human immunodeficiency virus
- Pregnancy or breastfeeding
- Any condition deemed unsuitable for the trial by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China, 215000
Actively Recruiting
Research Team
Y
Yang XU
CONTACT
B
Biqi ZHOU
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
PREVENTION
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here